The short version of mitochondrial biogenesis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Within a coral head, the genetically identical polyps reproduce asexually, either by budding (gemmation) or by dividing, whether longitudinally or transversely. Budding involves splitting a smaller polyp from an adult. As the new polyp grows, it forms its body parts. The distance between the new and adult polyps grows, and with it, the coenosarc (the common body of the colony). Budding can be intratentacular, from its oral discs, producing same-sized polyps within the ring of tentacles, or extratentacular, from its base, producing a smaller polyp. Division forms two polyps that each become as large as the original. Longitudinal division begins when a polyp broadens and then divides its coelenteron (body), effectively splitting along its length. The mouth divides and new tentacles form. The two polyps thus created then generate their missing body parts and exoskeleton. Transversal division occurs when polyps and the exoskeleton divide transversally into two parts. This means one has the basal disc (bottom) and the other has the oral disc (top); the new polyps must separately generate the missing pieces. Asexual reproduction offers the benefits of high reproductive rate, delaying senescence, and replacement of dead modules, as well as geographical distribution.
=== Dog domestication === Since the domestication of dogs, they have evolved alongside humans due to pressure from humans and the environment. This began by humans and wolves sharing the same area, with a pressure to coexist eventually leading to their domestication. Evolutionary pressure from humans led to many different breeds that paralleled the needs of the time, whether it was a need for protecting livestock or assisting in the hunt. Hunting and herding were a couple of the first reasons for humans artificially selecting for traits they deemed beneficial. This selective breeding does not stop there, but extends to humans selecting for certain traits deemed desirable in their domesticated dogs, such as size and color, even if they are not necessarily beneficial to the human in a tangible way. An unintended consequence of this selection is that domesticated dogs also tend to have heritable diseases depending on what specific breed they encompass.
=== Lawsuits against Joe Biden administration === In a 20-month span, Schmitt filed 25 lawsuits against the Biden administration with mixed results. The number of cases filed against the administration by Missouri during his tenure was second only to Louisiana.
Sources: en.wikipedia.org
Two of the most significant differences between puberty in females and puberty in males are the age at which it begins, and the major sex steroids involved, the androgens and the estrogens. Although there is a wide range of normal ages, females typically begin the process of puberty around age 10½; males at ages 11½–12. Puberty generally ends between 15–17 for females and 16–17 for males. Females attain reproductive maturity about four years after the first physical changes of puberty appear. In contrast, males accelerate more slowly but continue to grow for about six years after the first visible pubertal changes. For males, the androgen testosterone is the principal sex hormone; while testosterone is produced, all males' changes are characterized as virilization. A substantial product of testosterone metabolism in males is the estrogen estradiol. The conversion of testosterone to estradiol depends on the amount of body fat and estradiol levels in males are typically much lower than in females. The male "growth spurt" also begins later, accelerates more slowly, and lasts longer before the epiphyses fuse. Although males are on average 2 centimetres (0.8 in) shorter than females before puberty begins, adult men are on average about 13 centimetres (5.1 in) taller than women. Most of this sex difference in adult heights is attributable to a later onset of the growth spurt and a slower progression to completion, a direct result of the later rise and lower adult male levels of estradiol. The hormonal maturation of females is considerably more complicated than in males.
The narrower Russell Top 50 Mega Cap Index consists of the 50 largest companies in the Russell 3000 at the time of index reconstitution. As of April 30, 2026, the Russell Top 50 Mega Cap Index contained 51 constituents, with market caps ranging from $216.6 billion to $4.85 trillion. The even narrower Russell Top 10 Index consists of the 10 largest companies in the Russell 3000 at the time of index reconstitution. As of May 29, 2026, the Russell Top 10 Index contained 11 constituents, with market caps ranging from $873 billion to $4.93 trillion. A 2025 article by S&P Dow Jones Indices describes its own S&P 100, S&P 500 Top 50 (ticker: SP5T5), S&P 500 Top 20 (ticker: SP5T2), and S&P 500 Top 10 (ticker: SP5T1) indices as "mega-cap indices". As of May 29, 2026, the S&P 100 index's methodology required a minimum market cap of $22.7 billion, and the index's 101 constituents had actual market caps ranging from $55.1 billion to $5.13 trillion. As of May 29, 2026, the S&P 500 Top 50 Index contained 51 constituents, with market caps ranging from $92.3 billion to $5.13 trillion. Invesco issues an index ETF (NYSE Arca: XLG) that tracks the S&P 500 Top 50 Index. As of May 29, 2026, the S&P 500 Top 20 Index contained 21 constituents, with market caps ranging from $316 billion to $5.13 trillion. The S&P 500 Top 20 Select Index (ticker: SPXT2SUP) is a capped variant of the S&P 500 Top 20 Index, limiting any single company's weight in the index to a maximum of 22.5%, and limiting companies with weights above 4.5% to collectively constitute at most 48% of the index's weight.
=== Metabolism === Some data suggests neuronal overgrowth observed in autism may be caused by an increase in several growth hormones or impaired regulation of growth factor receptors. Some inborn errors of metabolism are associated with autism, but probably account for less than 5% of cases, although the precedence of this varies internationally with levels of consanguinity and it is thought to present its own endophenotype. Medical evidence has shown that autistic patients often present with abnormalities in glutathione-dependant redox metabolism, mitochondrial disorders, glucose 6 phosphate deficiency, Phenylketonuria and Propionic Acidemia among other metabolic abnormalities. Commonalities between both the genetic and epigenetic factors causing these metabolic disorders, and autism, are considered to be a potential reason for the high levels of comorbid presentation of autism in patients with a metabolic disorder. Many of the metabolic disorders implicated in autism also share a high degree of comorbidity to learning disabilities and other behavioural and neuropsychiatric concerns, most notably, catatonia (see also, catatonic autism), psychosis (see also, schizophrenia and autism) and depression.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.